CDX Models for Oncology Studies

Our cell line-derived xenograft (CDX) model studies can be offered as subcutaneous, disseminated, or orthotopic in both mice and rats, and can also be used in our humanized mouse models for evaluating immunotherapies within an intact human immune system.

Micropathology of breast tumor model, to represent the tumor models available in Charles River’s Cancer Model Database.

Cell Line-Derived Xenograft - Cancer Model Database

Support your in vitro, in vivo, and ex vivo studies with the following at your fingertips:

  • New user-friendly search and easy-to-navigate menus
  • New model data, including HLA typing, growth curves, and tumor images
  • New multi-parameter search options for all tumor model types (PDX and CDX)

Visit our Database

Human tumor CDX models involve implantation of commercially available tumor cell lines or patient-derived xenograft-derived cell lines into immunodeficient mice to conduct in vivo efficacy evaluation of potential cancer therapies, including targeted therapy, cytotoxic drugs, antibody therapies, and viral therapies.

Our broad range of tumor lines gives you a wide variety of testing alternatives for your agent. We evaluate our xenograft model portfolio on a regular basis for response to standards of care to aid the design of combination studies.

Cell Line Derived Xenograft (CDX) Model

CDX Models are tumor cell lines from commercial vendors or from patient-derived xenografts engrafted into immunodeficient mice.

Figure 1: Diagram of Cell Line-Derived Xenograft, CDX Model

In addition to helping you select the most appropriate CDX model for your agent, our scientific staff can fully profile your agent in a variety of tumor types or in combination with the appropriate clinical agent.

Charles River offers a wide range of histotypes, including broad models like non-small cell lung cancer, breast cancer or colon cancer, as well as tumor models with a high medical need like ovarian cancer, leukemia, lymphoma, or prostate cancer.

    Histotype Cell Line*
    Bladder SW780, RT112
    Brain U87 MG, U251
    Breast BT474, HCC-1806, HCC-1954, JIMT-1, MCF-7, MDA-MB-231, HCC70, MDA-MB436
    Colon CL-34, COLO 205, DLD-1, HCT 116, HCT-15, HT-29, LoVo, LS-174T, LS411N, RKO, SW48, SW480, SW620
    Endocervical KB
    Endometrial MFE-280
    Epidermoid Carcinoma A-431
    Esophageal OE19
    Ewing's Sarcoma RD-ES
    Gastric N87, SNU-5
    Head and Neck FaDu
    Leukemia ARH-77, HL-60, MOLM-13, MOLT-4, MV4-11, RS4;11, SET2, THP-1, HEL92.1.7, Kasumi-1, K562, OCI-AML3, MEC-1
    Liver HuH-7, SNU-398, Hep3B
    Lung (Non-small cell) A-427, A549, H1299, H1975, H226, H23, H292, H460, H520, H522, H647, H727, H810, HCC-44, H2122, H1568, SK-MES-1, H1650
    Lung (Small cell) H69, H82, H211, H526, SHP-77, DMS 114, H1963
    Lymphoma Daudi, DoHH-2, Granta 519, JEKO-1, KARPAS-299, Mino, Raji B, Ramos, REC-1, RL, SU-DHL-4, WSU-DLCL2, Namalwa, Z-138
    Melanoma A2058, A375, UACC-62
    Mesothelioma MSTO-211H
    Multiple Myeloma H929, OPM-2, RPMI 8226, MM1.s
    Neuroblastoma SK-N-AS, SK-N-MC
    Ovarian A2780, IGR0V1, OVCAR-3, OVCAR-5, SK-OV-3, TOV-21G, OV-90
    Osteosarcoma 143B
    Pancreas BxPc-3, HPAC, HPAF II, KP4, MIA PaCa-2, PSN-1, PANC1
    Prostate 22Rv.1, PC3, DU145
    Renal 786-0, G-401, G-402
    Sarcoma HT-1080, SJSA-1
    Thyroid 8505C, FTC-238
    * Note: Specially requested lines can be developed if a model of interest is not among those listed above.

    Although the models listed below have not yet been profiled for response to current standards of care, tumor growth curve data is available.

    Histotype Cell Line*
    Adrenal H295R
    Gastric MKN-45
    Leukemia NALM-6
    Liver HepG2
    Lung COR-L23, H1581, H1993, H441
    Melanoma CHL-1, COLO 800, IGR-1, IGR-37
    Multiple Myeloma KMS-11
    Neuroblastoma IMR-32
    Prostate LNCaP, VCaP
    Thyroid K1
    Uterine ECC-1, HEC-1-A, HEC-1-B
    * Note: Specially requested lines can be developed if a model of interest is not among those listed above.

Efficacy evaluation in CDX models can be combined with:

  • Hematology (CBC/Diff) analysis
  • Pharmacokinetic or bioavailability sampling and analysis
  • Histopathology or tissue sampling
  • Biomarker screening, sampling, or evaluation
  • In vivo microdialysis to determine pharmacological effects with high sensitivity and temporal resolution
  • In vivo implantable microdevices; simultaneous in vivo testing of multiple drugs, drug doses, or drug combinations in a single tumor


Graph showing HCT116 colon carcinoma standard of care data, showing the output of Charles Rivers extensive Standard of Care Database for use in combination design in cell-line derived xenograft CDX models.

Figure 2: Charles River’s CDX models have extensive standard of care data for combination design

Multichannel pipette injecting liquid into a microtiter plate for oncology research.

On Demand Oncology Webinar
Integrated Approaches: Leveraging In Vitro and Ex Vivo Tools for Oncology Research.

Watch the Webinar

If you’re looking to purchase oncology research models for use in your own efficacy studies, please visit our research models pages or see our xenograft data collection for help in selecting the best animal model.


Frequently Asked Questions (FAQs) for CDX Models: